PDCD1 and neoplasm: Blood tumor mutational burden estimated by NCC-GP150 correlated well with tissue tumor mutational burden calculated by whole-exome sequencing, and a blood tumor mutational burden of 6 or higher was positively associated with clinical benefits of anti–PD-1 and anti–PD-L1 therapy in patients with advanced non–small cell lung cancer.